<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T10:05:44Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10805574" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10805574</identifier>
        <datestamp>2024-01-23</datestamp>
        <setSpec>brjsurg</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Br J Surg</journal-id>
              <journal-id journal-id-type="iso-abbrev">Br J Surg</journal-id>
              <journal-id journal-id-type="publisher-id">bjs</journal-id>
              <journal-title-group>
                <journal-title>The British Journal of Surgery</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0007-1323</issn>
              <issn pub-type="epub">1365-2168</issn>
              <publisher>
                <publisher-name>Oxford University Press</publisher-name>
                <publisher-loc>US</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10805574</article-id>
              <article-id pub-id-type="pmcid">PMC10805574</article-id>
              <article-id pub-id-type="pmc-uid">10805574</article-id>
              <article-id pub-id-type="pmid">37376769</article-id>
              <article-id pub-id-type="pmid">37376769</article-id>
              <article-id pub-id-type="doi">10.1093/bjs/znad180</article-id>
              <article-id pub-id-type="publisher-id">znad180</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Original Article</subject>
                </subj-group>
                <subj-group subj-group-type="category-taxonomy-collection">
                  <subject>AcademicSubjects/MED00910</subject>
                </subj-group>
                <subj-group subj-group-type="category-taxonomy-collection">
                  <subject>Bjs/5</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Protocol for open-label randomized clinical trial of intensive surveillance <italic toggle="yes">versus</italic> standard postoperative follow-up in patients undergoing surgical resection for oesophageal and gastric cancer</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Markar</surname>
                    <given-names>Sheraz R</given-names>
                  </name>
                  <aff><institution>Nuffield Department of Surgery, University of Oxford</institution>, <addr-line>Oxford</addr-line>, <country country="GB">UK</country></aff>
                  <aff><institution>Department of Oesophago-Gastric Surgery, Oxford University Hospitals NHS Foundation Trust</institution>, <addr-line>Oxford</addr-line>, <country country="GB">UK</country></aff>
                  <xref rid="znad180-cor1" ref-type="corresp"/>
                  <!--sheraz.markar@nds.ox.ac.uk-->
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Guazzelli</surname>
                    <given-names>Alice</given-names>
                  </name>
                  <aff><institution>Nuffield Department of Surgery, University of Oxford</institution>, <addr-line>Oxford</addr-line>, <country country="GB">UK</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8635-7953</contrib-id>
                  <name>
                    <surname>Taylor</surname>
                    <given-names>Amy</given-names>
                  </name>
                  <aff><institution>Nuffield Department of Surgery, University of Oxford</institution>, <addr-line>Oxford</addr-line>, <country country="GB">UK</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Jones</surname>
                    <given-names>Laura Lloyd</given-names>
                  </name>
                  <aff><institution>Nuffield Department of Surgery, University of Oxford</institution>, <addr-line>Oxford</addr-line>, <country country="GB">UK</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Dutton</surname>
                    <given-names>Susan</given-names>
                  </name>
                  <aff><institution>Oxford Clinical Trials Research Unit, University of Oxford</institution>, <addr-line>Oxford</addr-line>, <country country="GB">UK</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Jogarah</surname>
                    <given-names>Vidoushee</given-names>
                  </name>
                  <aff><institution>Oxford Clinical Trials Research Unit, University of Oxford</institution>, <addr-line>Oxford</addr-line>, <country country="GB">UK</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2950-0733</contrib-id>
                  <name>
                    <surname>Brittain</surname>
                    <given-names>Clare</given-names>
                  </name>
                  <aff><institution>Oxford Clinical Trials Research Unit, University of Oxford</institution>, <addr-line>Oxford</addr-line>, <country country="GB">UK</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Maynard</surname>
                    <given-names>Nick</given-names>
                  </name>
                  <aff><institution>Nuffield Department of Surgery, University of Oxford</institution>, <addr-line>Oxford</addr-line>, <country country="GB">UK</country></aff>
                  <aff><institution>Department of Oesophago-Gastric Surgery, Oxford University Hospitals NHS Foundation Trust</institution>, <addr-line>Oxford</addr-line>, <country country="GB">UK</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Cromwell</surname>
                    <given-names>David</given-names>
                  </name>
                  <aff><institution>Clinical Effectiveness Unit, Royal College of Surgeons of England, London School of Hygiene and Tropical Medicine</institution>, <addr-line>London</addr-line>, <country country="GB">UK</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Landeiro</surname>
                    <given-names>Filipa</given-names>
                  </name>
                  <aff><institution>Health Economics Research Centre, University of Oxford</institution>, <addr-line>Oxford</addr-line>, <country country="GB">UK</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Underwood</surname>
                    <given-names>Tim</given-names>
                  </name>
                  <aff><institution>Department of Surgery, University of Southampton</institution>, <addr-line>Southampton</addr-line>, <country country="GB">UK</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5143-5448</contrib-id>
                  <name>
                    <surname>Lagergren</surname>
                    <given-names>Jesper</given-names>
                  </name>
                  <aff><institution>Department of Molecular Medicine, Karolinska Institutet</institution>, <addr-line>Stockholm</addr-line>, <country country="SE">Sweden</country></aff>
                  <aff><institution>Department of Surgery, Kings College London</institution>, <addr-line>London</addr-line>, <country country="GB">UK</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gleeson</surname>
                    <given-names>Fergus</given-names>
                  </name>
                  <aff><institution>Department of Radiology, Oxford University Hospitals NHS Trust</institution>, <addr-line>Oxford</addr-line>, <country country="GB">UK</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Moss</surname>
                    <given-names>Alan</given-names>
                  </name>
                  <aff><institution>Action Against Heartburn, Patient Association</institution>, <addr-line>London</addr-line>, <country country="GB">UK</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Crosby</surname>
                    <given-names>Tom</given-names>
                  </name>
                  <aff><institution>Department of Oncology, Cardiff and Vale University Health Board</institution>, <addr-line>Cardiff</addr-line>, <country country="GB">UK</country></aff>
                  <on-behalf-of>on behalf of the SARONG study group</on-behalf-of>
                </contrib>
              </contrib-group>
              <author-notes>
                <corresp id="znad180-cor1"><italic toggle="yes">Correspondence to:</italic> Sheraz R. Markar, Nuffield Department of Surgery, Churchill Hospital, Old Road, Headington, Oxford OX3 7LE, UK (e-mail: <email>sheraz.markar@nds.ox.ac.uk</email>)</corresp>
              </author-notes>
              <pub-date pub-type="collection">
                <month>10</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="epub" iso-8601-date="2023-06-28">
                <day>28</day>
                <month>6</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>28</day>
                <month>6</month>
                <year>2023</year>
              </pub-date>
              <volume>110</volume>
              <issue>10</issue>
              <fpage>1359</fpage>
              <lpage>1360</lpage>
              <history>
                <date date-type="received">
                  <day>15</day>
                  <month>4</month>
                  <year>2023</year>
                </date>
                <date date-type="accepted">
                  <day>18</day>
                  <month>5</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s) 2023. Published by Oxford University Press on behalf of BJS Foundation Ltd.</copyright-statement>
                <copyright-year>2023</copyright-year>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
              </permissions>
              <self-uri xlink:href="znad180.pdf"/>
              <funding-group>
                <award-group award-type="grant">
                  <funding-source>
                    <institution-wrap>
                      <institution>Health Technology Assessment</institution>
                      <institution-id institution-id-type="DOI">10.13039/501100000664</institution-id>
                    </institution-wrap>
                  </funding-source>
                </award-group>
              </funding-group>
              <counts>
                <page-count count="2"/>
              </counts>
            </article-meta>
          </front>
          <body>
            <p>Despite recent improvements in oncological and surgical treatment for patients with oesophageal and gastric cancer, 60 per cent of those with locally advanced disease who are treated with curative intent will develop tumour recurrence and die within 3 years of completing treatment. In the absence of robust scientific evidence, national or international guidelines have failed to reach consensus on the optimal surveillance strategy after primary treatment of oesophageal or gastric cancer.</p>
            <p>The primary research question of the proposed RCT is: does the routine use of a structured follow-up programme with regular radiological and endoscopic investigations improve survival in patients who have had surgical treatment for oesophageal or gastric cancer with curative intent?</p>
            <p>The aim is to assess whether structured follow-up, including radiological and endoscopic investigations, after completion of treatment with curative intent improves survival in patients with oesophageal or gastric cancer. The secondary aims are to determine the impact of structured post-treatment surveillance on the detection and treatment of cancer recurrence and health-related quality of life, including anxiety, and to assess the cost-effectiveness of routine clinical, radiological, and endoscopic investigations compared with the current practice.</p>
            <p>A national, prospective, multicentre RCT of structured follow-up, including radiological and endoscopic investigations, <italic toggle="yes">versus</italic> standard clinical follow-up will be undertaken. The setting will be at least 24 large oesophagogastric cancer centres in the UK. The aim is to recruit 952 patients receiving surgical resection for curatively intended treatment of oesophageal or gastric cancer with or without neoadjuvant/adjuvant chemo(radio or immuno)therapy. At 4–12 weeks after surgery for oesophageal or gastric cancer, patients will be assessed for eligibility for inclusion in the trial. Patients will be randomized 1 : 1 to receive either intensive follow-up for up to 3 years, with clinical and CT investigation every 6 months and endoscopy at 12 months, or to current standard National Health Service follow-up, which comprises clinical review at 6 and 12 months followed by targeted investigation as required based on the onset of new symptoms. The primary outcome is 3-year all-cause mortality and secondary outcomes include health-related quality of life (including anxiety), 3-year disease-specific mortality, pattern and treatment of tumour recurrence, and cost-effectiveness of follow-up in both study arms. Patients will be followed up either in clinic or via telephone at baseline, and 6, 12, 18, 24, 30, and 36 months after randomization.</p>
            <p>The total duration of the trial is 80 months. Recruitment will last 32 months and there will be a formal stop/go review of the internal pilot in month 15 of the project (9th month of recruitment) to ensure that, at a minimum, 9 centres are active and recruiting at least 2 patients per centre per month. Data from patients in the internal pilot phase will be included in the final analysis.</p>
            <p>It is anticipated that the study results will change national guidelines for oesophageal and gastric cancer and thus affect over 4000 patients who undergo surgery in the UK annually. The findings of this RCT will inform national and international guidelines for patients with oesophageal and gastric cancer, as this will be the first trial to provide robust evidence concerning the value of surveillance in this population.</p>
          </body>
          <back>
            <sec id="znad180-s0">
              <title>Funding</title>
              <p>This study is funded by National Institute for Health and Care Research Health Technology Assessment.</p>
            </sec>
            <sec id="znad180-s1">
              <title>Author contributions</title>
              <p>Sheraz Markar (Conceptualization, Funding acquisition, Investigation, Methodology, Resources, Supervision, Writing—original draft, Writing—review &amp; editing), Alice Guazzelli (Investigation, Project administration, Writing—review &amp; editing), Amy Taylor (Funding acquisition, Project administration, Writing—review &amp; editing), Laura Lloyd Jones (Methodology, Project administration, Writing—review &amp; editing), Susan Dutton (Formal analysis, Writing—review &amp; editing), Vidoushee Jogarah (Formal analysis, Investigation, Writing—review &amp; editing), Clare Brittain (Methodology, Project administration, Writing—review &amp; editing), Nick Maynard (Conceptualization, Funding acquisition, Methodology, Writing—review &amp; editing), David Cromwell (Conceptualization, Funding acquisition, Writing—review &amp; editing), Filipa Landeiro (Formal analysis, Writing—review &amp; editing), Tim Underwood (Funding acquisition, Investigation, Writing—review &amp; editing), Jesper Lagergren (Conceptualization, Funding acquisition, Writing—review &amp; editing), Fergus Gleeson (Funding acquisition, Writing—review &amp; editing), Alan Moss (Funding acquisition, Writing—review &amp; editing), and Tom Crosby (Funding acquisition, Writing—review &amp; editing).</p>
            </sec>
            <sec id="znad180-s2">
              <title>Disclosure</title>
              <p>The authors declare no conflict of interest.</p>
            </sec>
            <sec sec-type="data-availability" id="znad180-s3">
              <title>Data availability</title>
              <p>There are no new data in this manuscript.</p>
            </sec>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
